Wenzhou Kangning Hospital Co Ltd
Wenzhou Kangning Hospital Co Ltd operates as a healthcare provider, delivering medical services and pharmaceuticals to patients in China.
Business. Wenzhou Kangning Hospital Co Ltd (2120.HK) is a healthcare facilities and services company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, providing medical services and related facilities. Its headquarters are located in Wenzhou, China. The company does not disclose specific operating segments or geographic revenue breakdowns in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Wenzhou Kangning Hospital Co Ltd (2120.HK) is a healthcare facilities and services company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, providing medical services and related facilities. Its headquarters are located in Wenzhou, China. The company does not disclose specific operating segments or geographic revenue breakdowns in the provided data.
Wenzhou Kangning Hospital Co Ltd has a fully diluted share count of 72,358,900 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. Without access to key financial ratios such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess the company's performance relative to industry benchmarks.
The company's revenue concentration by segment or geography is not disclosed in the available data. Without segmental or geographic revenue breakdowns, it is not possible to evaluate exposure to specific markets or business lines.
Growth trajectory data is not available in the outlook section. No numeric deltas or revenue history are provided to assess the company's current or future performance.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. Dilution risk is currently low, and no adjustments have been applied to valuation metrics.
Recent events, such as filings or transcripts, are not disclosed in the available data. No specific events or disclosures are available to inform the company's current strategic or financial position.
- The company has no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
- Profitability and return metrics are not available, making it difficult to assess performance relative to industry benchmarks.
- Revenue concentration by segment or geography is not disclosed, limiting visibility into market exposure.
- Growth trajectory data is not available, and no numeric deltas or revenue history are provided to assess performance.
- No recent events or filings are disclosed, limiting insight into the company's strategic or financial developments.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥1.65B, +3,6% YoY; Operating income −25,7% YoY.
- ▍Revenue ¥1.65B, +3,6% YoY
- ▍Operating income −25,7% YoY
- ▍Net income −23,7% YoY
- ▍Free cash flow −457,5% YoY
- ▍Net margin 4.0%
Revenue ¥1.60B, +7,5% YoY; Operating income +518,9% YoY.
- ▍Revenue ¥1.60B, +7,5% YoY
- ▍Operating income +518,9% YoY
- ▍Net income +454,9% YoY
- ▍Free cash flow +91,2% YoY
- ▍Net margin 5.4%
Revenue ¥1.48B, +14,4% YoY; Operating income −82,3% YoY.
- ▍Revenue ¥1.48B, +14,4% YoY
- ▍Operating income −82,3% YoY
- ▍Net income −155,0% YoY
- ▍Free cash flow −196,9% YoY
- ▍Net margin -1.6%
Revenue ¥1.30B; Operating income ¥92.5M.
- ▍Revenue ¥1.30B
- ▍Operating income ¥92.5M
- ▍Net margin 3.4%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Wenzhou Kangning Hospital Co Ltd Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Weili GuanExecutive Chairman of the Board